1. Background {#sec1}
=============

Cancer is the second leading cause of death worldwide \[[@B1]\], with more than 60% of cases being reported from Africa, Asia, and Central and South America. These regions account for about 70% of cancer deaths worldwide \[[@B2]\]. It was estimated that between 2000 and 2020 there would be 75% increase of cancer incidence in resource-limited countries \[[@B3]\]. Mortality rate due to cancer is more in resource-limited countries than in developed countries \[[@B4]\]. It is estimated that by 2020, about 70% of deaths associated with cancer diseases would be from resource-limited countries and cancer survival rate would be 50% less than that of the developed countries \[[@B5]\].

In Tanzania, by the year 2008, there were 21,180 new cases of cancer per 42.5 million people \[[@B6]\]. In 2014, deaths due to cancers were reported to be 9,100 and 10,800 for men and women, respectively \[[@B7]\]. Cervical and breast cancers were leading causes of death among women while esophagus and head and neck cancers were leading causes of death among men \[[@B7]\]. Mortality among cancer patients is reported to be significantly high within the first 90 days of therapy \[[@B8], [@B9]\], and the incidence is reported to be 10.3 times higher in patients with one comorbidity (renal disease, heart disease, chronic bronchitis, or mucositis) than those without comorbidity and can increase to 24.1 times higher with the increase in number of comorbidities \[[@B8]\]. Other factors associated with mortality among cancer patients on therapy include the type of cancer, anticancer regimen, age, performance status, anemia, and neutropenia \[[@B8], [@B10], [@B11]\]. Furthermore, outpatients have been reported to have higher mortality rate than the inpatients which is associated with the lack of supportive care among outpatients \[[@B8], [@B10]\].

The number of cancer patients receiving medication at the oncology department of Bugando Medical Center (BMC) has increased due to the availability of chemotherapy, diagnostic techniques, and improved infrastructure for cancer management. However, data on mortality and its associated factors within 90 days of starting chemotherapy is still limited. Here, we are reporting mortality and factors associated with it within 90 days of therapy among cancer patients attending the oncology department of BMC. The spectrum of bacterial pathogens causing infections among these patients has also been determined.

2. Methods {#sec2}
==========

This was a hospital-based cross-sectional study with a follow-up component which was conducted from August 2017 to May 2018 at the BMC oncology department. The unit attends about 100-150 cancer patients per month and receives up to 25 new patients per month (<http://www.bugandomedicalcentre.go.tz/index.php?bmc=24>). The study enrolled all patients with age above 12 years, histologically confirmed to have cancer and scheduled to start chemotherapy.

The minimum number of patients to be enrolled in the study was obtained using Kish and Lisle formula of 1965 \[[@B12]\]. The prevalence of mortality among cancer patients of 8% was substituted, and the minimum number of patients obtained was 82 \[[@B9]\].

2.1. Data Collection {#sec2.1}
--------------------

A total of 114 patients were eligible to start cancer therapy at the BMC oncology department during the study period; however, we enrolled 111 patients because 3 patients declined participation.

At enrollment, physical and clinical examination was done; blood pressure was measured using a digital blood pressure monitor CHU 304 (Citizen Systems Japan Co. Ltd.) that has been clinically validated by the European Society of Hypertension protocol of 2010. Body temperature was measured by a digital thermometer MDD 93/42/EEC, "0197" (Holding Corp. GmbH (Hamburg)), and body weight and height were measured using DETECTO machine (Webb City, MO, USA). The data on type, stage of cancer, treatment regimen, and duration of therapy were recorded from the patients\' file. At each visit, patients were evaluated for signs and symptoms of infections, especially fever.

At baseline, the following investigations were done: full blood picture (FBP), and urine and blood culture as per the BMC management protocol. Another FBP was taken during follow-up visits, and for patients who developed signs and symptoms of infections, blood and urine were collected for culture following the standard operating procedures of the accredited microbiology laboratory of BMC. Blood cell counts were analyzed by the use of Cell-Dyn 1800 automated hematology analyzer (Abbott Diagnostics, Illinois, USA). Drug susceptibility testing was done using Kirby Bauer disk diffusion technique and interpreted using the Clinical and Laboratory Standards Institute (CLSI) guidelines \[[@B13]\].

2.2. Data Management and Analysis {#sec2.2}
---------------------------------

Laboratory data were recorded in a laboratory workbook and then entered onto the Excel spreadsheet for cleaning and coding before being transferred to STATA version 13 for analysis. Continuous data like blood pressure, body weight, Karnofsky score, temperature, white blood cell count, and neutrophil count were presented as medians and interquartile ranges and compared by the Wilcoxon rank-sum test. Categorical variables such as sex, marital status, occupation, and level of education were presented as frequency (percent) and compared by chi-square or Fisher\'s exact test. A *p* value of \<0.05 was considered statistically significant.

3. Ethics Approval and Consent to Participate {#sec3}
=============================================

The protocol for this study was ethically approved by the joint CUHAS/BMC ethics and scientific review committee with certificate number CREC/228/2017. Permission to carry out the study was also sought from the management of the BMC and the oncology department. Written informed consent was obtained from the participants after being informed about the study objectives and procedures. For all participants aged less than 18 years, consents were sought from parents/guardians and assent was requested from the participant.

4. Results {#sec4}
==========

4.1. Social Demographic and Baseline Clinical Data {#sec4.1}
--------------------------------------------------

Out of 111 enrolled patients, 102 were included in the final analysis. A total of 5 patients could not start cancer therapy due to financial reasons; two were lost to follow-up, one died before therapy was initiated and one shifted to a referral cancer hospital (Ocean Road Cancer Institute, Dar es Salaam, Tanzania).

The median age (IQR) of the study population was 50 (30-60) years. The majority were females (76, 74.5%), and (82 80.3%) had primary school education. The majority (70, 68.6%) were married. The majority of patients had solid cancers (94.1%), and about one-third of patients reported at the oncology department while at cancer stage IV. All patients in stage IV of cancer received palliative care and low-dose chemotherapy calculated based on their performance status. Regarding various clinical parameters, the median body temperature (IQR) was 36.2°C (35.6-36.6), with median neutrophil (IQR) count of 3.0 × 10^9^/L (2.1-4.1) and median Hb 11.6 g/dL (10.2-12.6). Out of 102 patients, 19 (18.6%) were HIV positive.

4.2. Types of Cancer Diagnosed {#sec4.2}
------------------------------

The commonest type of cancer diagnosed was gynecological cancer (47, 46.1%) which was led by cervical cancer (40, 39%), followed by head and neck cancer (12, 11.8%) led by squamous cell carcinoma of the head and neck (6, 4.9%). Breast cancer was diagnosed in 11 (10.8%) ([Table 1](#tab1){ref-type="table"}).

4.3. Mortality within 90 Days of Starting Chemotherapy {#sec4.3}
------------------------------------------------------

Mortality within 90 days of starting therapy among cancer patients at the oncology department was 12 (11.8%). The age of those who died ranged between 33 and 76 years. All patients who died in the current study had solid cancer and anemia at baseline with hemoglobin range from 7.3 to 11.4 g/dL. The majority (11, 91%) reported at the oncology department at advanced stage, i.e., cancer stages 3 and 4. A total of 9 (75%) had a performance status below 80% by Karnofsky score ([Table 2](#tab2){ref-type="table"}).

4.4. Culture Results and Mortality within 90 Days of Starting Chemotherapy {#sec4.4}
--------------------------------------------------------------------------

Among the 102 nonrepetitive blood cultures done at baseline, 7 (6.9%) were culture positive. *S. aureus* (4, 3.9%) was the most frequently detected pathogen, followed by *E. coli* and *Pseudomonas aeruginosa*, 2 (1.9%) and 1 (1%), respectively. Regarding urine culture, 13/102 (12.7%) patients had significant bacteriuria at baseline. *S. aureus* (7, 6.9%) was the most frequently isolated bacteria species, followed by *E. coli* (5, 4.9%) and *Pseudomonas aeruginosa* (1, 1%). Of the 18 patients with bacterial infections, either UTI or blood stream infections, 3/18 (16.6%) died compared to 9/84 (10.8%) without bacterial infection, *p* = 0.244. Of the patients with bacterial infections who died, one had *S. aureus* blood stream infection and two had significant bacteriuria, one due to *P. aeruginosa* and another due to *E. coli*.

4.5. Factors Associated with Mortality {#sec4.5}
--------------------------------------

Significant proportion of patients with head and neck cancer died compared to patients with other types of cancer (33.3% (4/12) vs. 8.9% (8/90), *p* = 0.014). The median hemoglobin level of patients who died was significantly lower than the median hemoglobin level of patients who survived (10 (9.3-10.8) g/dl vs. 11.8 (10.5-12.7) g/dl, *p* = 0.001) ([Table 3](#tab3){ref-type="table"}).

5. Discussion {#sec5}
=============

Mortality within 90 days of starting chemotherapy among cancer patients in the current study was found to be 12%. The mortality reported was almost similar to 11% that was reported by Kuderer et al. from the United States among cancer patients on therapy in 2006 and slightly higher than 8% which has recently been reported from South Africa \[[@B8], [@B14]\]. Furthermore, the mortality was significantly high compared to 7.2% reported by the International Agency for Research on Cancer from Sub-Saharan Africa in the global cancer statistics of 2012 \[[@B15]\]. Additionally, similar mortality was reported in the study done in West Africa 8 years ago which reported the mortality of 10% \[[@B16]\]. Low functional status due to cancer itself and the toxicity brought by the therapy collectively compromise the health of the patients and might lead to high mortality observed after therapy initiation in the current study.

As previously reported in the world cancer report of 2012 \[[@B17]\], the current study found solid cancers to be the predominant cancer type at BMC. However, contrary to the world report which observed the commonest solid cancer to be lung cancer \[[@B18], [@B19]\], this study observed cervical cancer to be the commonest solid cancer. In Tanzania, cervical cancer has been the leading cancer in the past one decade \[[@B20], [@B21]\]. The ongoing national campaign regarding screening for cervical cancer could explain the findings. Furthermore, it should be noted that maybe lung cancer is underreported due to the little attention that is given to it.

Contrary to high mortality that has been reported in several studies \[[@B8], [@B22]\] among patients with hematological malignancies, in the current study, all patients with hematological malignancy survived within 90 days of therapy. Hematological malignancy is known to have higher mortality than solid cancer, the reason being that hematological malignancies are associated with both depletion and impaired function of neutrophils due to cancer itself and the toxicity of therapy \[[@B22], [@B23]\]. The mortality data for patients with hematological malignancy in the current study should be carefully interpreted due to the limited number of patients.

In the current study, severe neutropenia was not observed. Neutropenia has been associated with increased mortality in many studies \[[@B22], [@B23]\]. In the current study, the use of granulocyte colony-stimulating factors among patients with reduced number of neutrophil before starting therapy prevented severe neutropenia hence reduced mortality of these patients.

As in a previous study in the United States and Greece, significantly more mortality was observed among patients in 5-fluorouracil treatment \[[@B24]\]. The toxicity induced by 5-fluorouracil such as stomatitis, mucositis, and diarrhea \[[@B24]\] could partly explain the observation. As observed in a previous study in France \[[@B25]\], patients with carcinoma of the head and neck had two times odds of dying than patients with other cancers.

This study observed increased mortality in head and neck cancer patients; this could be due to the fact that the disease is close to vital organs with possibility of impairment in swallowing and breathing \[[@B26]\]. Additionally, significantly high mortality among patients with head and neck cancers in this study could be contributed by late stage presentation at the oncology department, advanced age, and poor performance status. Late stage presentation has been documented as the main predictor of mortality \[[@B26]\]. Furthermore, advanced age has been noted as the poor prognostic factor among patients with head and neck cancer \[[@B27]\].

As it was documented in a meta-analysis where anemia was found to be the leading cause of mortality \[[@B28]\], in the current study, all patients who died had anemia at the baseline. This could be due to the fact that anemia leads to the hypoxic state which reduces the amount of drug delivered to the cell and hence reduces the therapy response \[[@B29], [@B30]\]. The findings of this study regarding high mortality among anemic patients confirm what has been reported in previous studies \[[@B28], [@B31]\]. Furthermore, anemia is associated with fatigue which causes the inability to perform daily activities among cancer patients and hence reduces the quality of life of patients and increases mortality \[[@B29], [@B30]\].

6. Conclusion {#sec6}
=============

The mortality of cancer patients within 90 days of therapy was slightly higher than that of patients in Sub-Saharan Africa and more pronounced in patients with anemia at baseline, use of 5-fluorouracil, poor performance status, and diagnosis of head and neck cancers necessitating close follow-up of these patients. Furthermore, a study focused on hematological cancers from developing countries to provide data on mortality is recommended.

The authors would like to acknowledge the support provided by the Department of Oncology of the Bugando Medical Centre and the technical support of Mr. Vitus Silago from the Department of Microbiology and Immunology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania. This work was supported through the DELTAS Africa Initiative grant \# DEL-15-011 of THRiVE-2 to MJC. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences\' Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa\'s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust grant \# 107742/Z/15/Z and the UK Government.

BMC:

:   Bugando Medical Centre

CLSI:

:   Clinical and Laboratory Standards Institute

FBP:

:   Full blood picture

IQR:

:   Interquartile range.

Data Availability
=================

The data is available upon request and the request should be made to the Director of Research and Innovation, Catholic University of Health and Allied Sciences.

Ethical Approval
================

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was given ethical clearance by the joint CUHAS/BMC ethics and scientific review committee with certificate number CREC/228/2017. Permission to carry out the study was also sought from the management of the Bugando Medical Centre and the oncology department.

Consent
=======

Written informed consent was obtained from participants after being informed about the study objectives and procedures. For all participants aged less than 18 years, consents were sought from parents/guardians and assent was requested from the participant.

Disclosure
==========

The funding body had no role in the design of the study and data collection, analysis and interpretation of the data, and in writing the manuscript.

Conflicts of Interest
=====================

The authors declare that they have no conflicts of interest.

Authors\' Contributions
=======================

MJC, MFM, SEM, and BL designed the work. MJC, MFM, and VS recruited the patients and performed laboratory investigations. MJC and BL managed the patients. MFM, RK, and SEM analyzed and interpreted the data. MJC and MFM wrote the first draft of the manuscript which was critically reviewed by RK, VS, BL, and SEM. All authors read and approved the final version of the manuscript.

###### 

Description of type of cancer seen during the study period.

  Variable                                       Frequency (*N*)   Percent (%)
  ---------------------------------------------- ----------------- -------------
  *Gynecological cancers*                        **47**            **46**
  Cancer of the cervix                           40                39
  Uterine cancer                                 5                 4.9
  Ovarian cancer                                 1                 1
  Choriocarcinoma                                1                 1
  *Head and neck cancers*                        **12**            **12**
  Squamous cell carcinoma of the head and neck   5                 4.9
  Adenocarcinoma of the head and neck            3                 2.9
  Retinoblastoma                                 2                 2
  Nasopharyngeal cancer                          1                 1
  Sinonasal cancer                               1                 1
  *Connective tissue cancers (sarcoma)*          **12**            **12**
  Kaposi\'s sarcoma                              6                 6
  Malignant melanoma                             2                 2
  Malignant phyllodes                            1                 1
  Fibrosarcoma                                   1                 1
  Osteosarcoma                                   1                 1
  Chondrosarcoma                                 1                 1
  *Breast cancer*                                **11**            **11**
  *Gastrointestinal cancers*                     **10**            **10**
  Hepatocellular cancer                          4                 4
  Pancreatic cancer                              2                 2
  Colon cancer                                   2                 2
  Esophageal cancer                              1                 1
  Biliary rhabdomyosarcoma                       1                 1
  *Hematolymphoid malignancies*                  **6**             **6**
  Hodgkin lymphoma                               2                 2
  Chronic myeloid leukemia                       1                 1
  Acute myeloid leukemia                         1                 1
  Burkitt\'s lymphoma                            1                 1
  Non-Hodgkin lymphoma                           1                 1
  *Genital and reproductive cancer*              **2**             **2**
  Perianal cancer                                1                 1
  Prostate cancer                                1                 1
  *Lung cancer*                                  **1**             **1**

###### 

Baseline characteristics for patients who died within 90 days.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                         Patient identification                                                                                                                                                                                                            
  -------------------------------- ------------------------ ----------------- ----------------------- -------------------- ----------------- ------------------- ------------------ ---------------------------- ----------------- ----------------- --------------- --------------------------------------
  Age (years)                      76                       71                52                      43                   65                50                  49                 62                           51                51                52              33

  BMI (kg/m^2^)                    18                       29                22.2                    25                   21                25                  27.7               23.2                         25.2              22.8              24.8            20.8

  Cancer type                      Nasopharyngeal cancer    Breast cancer     GIT metastatic cancer   Malignant melanoma   Cervical cancer   Pancreatic cancer   Sinonasal cancer   Adenocarcinoma of the nose   Cervical cancer   Cervical cancer   Lung cancer     Squamous cell carcinoma of the cheek

  Type of therapy                                                                                                                                                                                                                                                    

  Type 1\                          5-Fluorouracil\          Carboplatin       Docetaxel\              Carboplatin          Cisplatin\        Gemcitabine\        Cisplatin\         Cisplatin                    Cisplatin\        Cisplatin\        Docetaxel\      Cisplatin\
  Type 2\                          Cisplatin\                                 Dexamethasone                                Dacarbazine       5-Fluorouracil      Radiotherapy                                    Radiotherapy      5-Fluorouracil    Dexamethasone   5-Fluorouracil\
  Type 3                           Paclitaxel                                                                                                                                                                                                                        Dexamethasone

  Stage of cancer                  3                        4                 4                       3                    3                 3                   4                  4                            2                 3                 3               3

  Baseline neutrophil (×10^9^/L)   3.51                     19.7              3.2                     2.38                 2.94              5.65                0.75               2.83                         5.79              3.21              3.05            1.47

  Neutrophil 1 (×10^9^/L)          2.9                      19.8              2.87                    3.92                 1.09              5.17                1.65               2.6                          5.8               2.25              2.4             1.2

  Neutrophil 2 (×10^9^/L)          ---                      ---               1.35                    2.41                 1.08              ---                 1.41               1.6                          7.46              ---               1.3             1.7

  Neutrophil 3 (×10^9^/L)          ---                      ---               ---                     1.13                 ---               ---                 ---                3.17                         2.69              ---               ---             ---

  Neutrophil 4 (×10^9^/L)          ---                      ---               ---                     ---                  ---               ---                 ---                3.07                         3.91              ---               ---             ---

  Neutrophil 5 (×10^9^/L)          ---                      ---               ---                     ---                  ---               ---                 ---                1                            ---               ---               ---             ---

  Baseline Hb (g/dL)               9.6                      11.1              11                      9.9                  10.1              9                   9.1                10.5                         7.3               10.3              11.4            9.5

  Baseline WBC (×10^9^/L)          6.14                     4.58              4.8                     4.29                 5.33              8.37                2.92               4.8                          8.84              5.1               4.97            2.29

  Karnofsky score (%)              80                       20                60                      80                   90                70                  90                 70                           80                90                80              70

  Blood culture                    No growth                No growth         No growth               No growth            No growth         No growth           No growth          No growth                    No growth         No growth         *S. aureus*     No growth

  Urine culture                    No growth                *P. aeruginosa*   No growth               No growth            No growth         No growth           No growth          No growth                    No growth         No growth         No growth       *E. coli*

  Body temperature(°C)             36                       38.2              37.1                    36.3                 36.8              37.2                37                 35.2                         35.5              36.7              35.3            36.8
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Factors associated with mortality within 90 days of therapy.

  Variable                               Dead (12)            Alive (90)           *p* value
  -------------------------------------- -------------------- -------------------- -----------
  HIV status                                                                       
   Unknown (21)                          3 (14.3)             18 (85.7)            
   Negative (62)                         9 (14.5)             53 (85.5)            
   Positive (19)                         0 (0)                19 (100)             0.211
  Baseline body temperature (°C)         36.2 \[35.4-36.4\]   36.2 \[35.7-36.7\]   0.4023
  BMI                                    23.8 \[21.7-25\]     22.9 \[20.2-25.9\]   0.453
  Cancer type                                                                      
   Others (90)                           8 (8.9)              82 (91.1)            
   Head and neck (12)                    4 (33.3)             8 (66.67)            0.014
  Therapy type                                                                     
   Cisplatin (50)                        7 (14.0)             43 (86.0)            0.492
   5-Fluorouracil (10)                   4 (40.0)             6 (60.0)             0.004
   Paclitaxel (22)                       1 (4.5)              21 (95.5)            0.235
   Carboplatin (9)                       2 (22.2)             7 (77.8)             0.308
   Dacarbazine (4)                       1 (25.0)             3 (75)               0.402
   Docetaxel (6)                         2 (33.3)             4 (66.7)             0.091
  Karnofsky score (%)                    80 \[70-85\]         90 \[80-90\]         0.001
  Baseline Hb (g/dL)                     10 \[9.3-10.8\]      11.8 \[10.5-12.7\]   0.001
  Baseline white blood cell (×10^9^/L)   4.9 \[4.4-5.7\]      5.2 \[4-6.7\]        0.226
  Baseline neutrophil (×10^9^/L)         3.1 \[2.6-4.6\]      3 \[2-4.1\]          0.653
  Body temperature visit (°C)                                                      
   Visit 1                               36.6 \[36.1-37\]     36.4 \[35.9-36.8\]   0.852
   Visit 2                               36.7 \[36-36.9\]     36.2 \[35.8-36.8\]   0.677
   Visit 3                               36.1 \[36.1-36.3\]   36.3 \[35.8-36.8\]   0.565
   Visit 4                               36.3 \[35.5-37.1\]   36.2 \[35.7-36.6\]   0.758
   Visit 5                               35.2 \[35.2-35.2\]   36.4 \[35.9-37\]     0.490
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